AstraZeneca (AZN)
(Delayed Data from NSDQ)
$75.03 USD
+3.83 (5.38%)
Updated Apr 25, 2024 04:00 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Price, Consensus and EPS Surprise
AZN 75.03 +3.83(5.38%)
Will AZN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AZN
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Q1 GDP Increased Lower Than Expectations
Is "Bad News" Still "Good News" for the Market?
Other News for AZN
GLOBAL BROKER RATINGS: Stifel cuts Caterpillar; HSBC likes Ashtead
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and BioMarin Pharmaceutical (BMRN)
Life prolonging breast cancer drug recommended for PBS subsidy, but it is not time to celebrate
LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'
3 Best Healthcare Stocks to Buy in April 2024, According to Analysts